menu
    • menu

    Company profile for Vesper Bio

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vesper Bio is a clinical-stage biotech company that employs a sortilin inhibitor to rebalance progranulin levels in patients. In conditions where the sortilin receptor would otherwise reduce circulating and extracellular progranulin, Vesper Bio aims to address the underlying disease mechanisms. The company is at the forefront of sortilin biology, boasting a robust background in biopharma. Supported by an outstanding multinatio...
    Vesper Bio is a clinical-stage biotech company that employs a sortilin inhibitor to rebalance progranulin levels in patients. In conditions where the sortilin receptor would otherwise reduce circulating and extracellular progranulin, Vesper Bio aims to address the underlying disease mechanisms. The company is at the forefront of sortilin biology, boasting a robust background in biopharma. Supported by an outstanding multinational scientific advisory board, which includes prominent key opinion leaders, Vesper Bio is pioneering advancements in this field.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vesper BioDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    DK-1610 Copenhagen
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vesperbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vesperbio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vesper Bio Reports Positive Phase Ib/Iia Topline Data For VES001
    Vesper Bio Reports Positive Phase Ib/Iia Topline Data For VES001

    31 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-31/vesper-bio-announces-positive-phase-ibiia-topline-results-for-lead-candidate-ves001-for-frontotemporal-degeneration

    PHARMIWEB
    31 Oct 2025
    Share Share
    Vesper Bio Announces Successful Ph I Study for Frontotemporal Dementia Treatment
    Vesper Bio Announces Successful Ph I Study for Frontotemporal Dementia Treatment

    04 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vesper-bio-announces-successful-phase-i-study-for-potentially-disease-modifying-treatment-for-frontotemporal-dementia-302236963.html

    PR NEWSWIRE
    04 Sep 2024
    Share Share
    Vesper Bio Completes SAD In FTD Trial Of VES001 Drug Candidate
    Vesper Bio Completes SAD In FTD Trial Of VES001 Drug Candidate

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vesper-bio-announces-completion-of-single-ascending-dose-stage-in-trial-of-its-lead-candidate-ves001-a-potentially-disease-modifying-treatment-for-fronto-temporal-dementia-302158331.html

    PR NEWSWIRE
    30 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search